Tipiracil is a thymidine phosphorylase (TPase) inhibitor.
性状
Solid
IC50 & Target[1][2]
thymidine phosphorylase
体外研究(In Vitro)
Tipiracil is an inhibitor of thymidine phosphorylase. Tipiracil increases trifluridine exposure by inhibiting its metabolism by thymidine phosphorylase. The combination of Trifluridine and Tipiracil is a new oral treatment for metastatic colorectal cancer. Tipiracil prevents degradation of FTD through a first-pass effect as a thymidine phosphorylase inhibitor. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. Lee SJ, et al. Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1327-35.[2]. Raedler LA. Lonsurf (Trifluridine plus Tipiracil): A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer. Am Health Drug Benefits. 2016 Mar;9(Spec Feature):97-100.
溶解度数据
In Vitro: H2O : 1 mg/mL (4.12 mM; Need ultrasonic)DMSO : < 1 mg/mL (insoluble or slightly soluble)配制储备液